Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
In a recent randomized, double-blind, phase III clinical trials among patients with metastatic castration-resistant prostate cancer (CRPC) progressing on androgen-deprivation therapy or after docetaxel chemotherapy, abiraterone acetate was shown to significantly prolong radiographic progression free...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2014-09-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26988 |